Email this article Expert committee resolution on the duration of maintenance therapy for patients with locally advanced or metastatic urothelial cancer
- Issue: Vol 22, No 2 (2026)
- Pages: 134-136
- Section: RESOLUTION
- Published: 29.09.2026
- URL: https://oncourology.abvpress.ru/oncur/article/view/2081
- DOI: https://doi.org/10.17650/1726-9776-2026-22-2-134-136
- ID: 2081
Cite item
Open Access
Access granted
Subscription or Fee Access
References
- Bupathi M., Sura S., Ike C. et al. Real-world (rw) treatment (tx) patterns and overall survival (OS) in patients (pts) with locally advanced/metastatic urothelial carcinoma (la/mUC) treated with avelumab first-line maintenance (1LM): Updated results from the SPEAR Bladder II study. JCO Oncol Pract 2024;20(10 suppl):393. doi: 10.1200/OP.2024.20.10_suppl.393
- Barthélémy P., Thibault C., Fléchon A. et al. Real-world study of avelumab first-line maintenance treatment in patients with advanced urothelial carcinoma in France: overall results from the noninterventional AVENANCE study and analysis of outcomes by second-line treatment. Eur Urol Oncol 2025;8(2):407–16. doi: 10.1016/j.euo.2024.09.014
- Wakamiya T., Yamashita S., Kohjimoto Y., Hara I. Serum lactate dehydrogenase level prior to first-line chemotherapy for metastatic urothelial carcinoma is a prognostic factor for avelumab maintenance therapy: a multicenter retrospective study. Int J Urol 2025;32(8):997–1004. doi: 10.1111/iju.70086
- Grivas P., Barata P., Moon H. et al. Avelumab first-line maintenance for locally advanced or metastatic urothelial carcinoma: results from the real-World US PATRIOT-II study. Clin Genitourin Cancer 2024;22(6):102238. doi: 10.1016/j.clgc.2024.102238
- Moon H.H., Ike C., Dixon R.W. et al. Real-world retrospective study of clinical and economic outcomes among patients with locally advanced or metastatic urothelial carcinoma treated with first-line systemic anti-cancer therapies in the United States: results from the IMPACT UC-III study. Curr Oncol 2025;32(7):384. doi: 10.3390/curroncol32070384
- Zacchi F., Sordo A., Torresan I. et al. Clinical outcomes of avelumab and pembrolizumab in advanced urothelial cancer: an observational multicenter retro-prospective study on patients undergoing treatment in clinical practice (AVePEm study). Front Oncol 2025;15:1532421. doi: 10.3389/fonc.2025.1532421
- Taneda Y., Urabe F., Uchida N. et al. Clinical outcomes and treatment patterns of maintenance avelumab in locally advanced or metastatic urothelial carcinoma: a multicenter collaborative study. Jpn J Clin Oncol 2025;55(5):522–30. doi: 10.1093/jjco/hyaf008
- Powles T., Park S.H., Caserta C. et al. Avelumab first-line maintenance for advanced urothelial carcinoma: results from the JAVELIN Bladder 100 trial after ≥2 years of follow-up. J Clin Oncol 2023;41(19):3486–92. doi: 10.1200/JCO.22.01792
- Powles T., Hussain S.A., Climent M.A. et al. Three versus six cycles of platinum-based chemotherapy followed by avelumab maintenance as first-line treatment for advanced urothelial cancer: the phase II DISCUS trial. Ann Oncol 2026;37(2):250–9. doi: 10.1016/j.annonc.2025.10.011
- Bladder cancer. Clinical guidelines of the Russian Ministry of Health, 2023.
Supplementary files
